Hendrik V.
- Country
- The Netherlands
- Department
- Afd. Hematologie
Research Overview
- Phase III Randomized, Placebo-Controlled Study of Venetoclax with Induction and Consolidation Chemotherapy in Newly Diagnosed AML or MDS-EB2 Patients
- An Adaptive Phase 3, Randomized, Open-Label, Multicenter Study to Compare the Efficacy and Safety of Axicabtagene Ciloleucel versus Standard of Care Therapy as First-Line Therapy in Subjects with High-Risk Large B-Cell Lymphoma (ZUMA-23)
- Phase 3 Study of Zilovertamab Vedotin Plus R-CHP Versus R-CHOP in Untreated Diffuse Large B-Cell Lymphoma Patients
Data & Insights
Has run more than one trial at 69 of 242 partner sites.
Specializations
Hematologic Oncology
The investigator specializes in treating acute myeloid leukemia (AML), with particular focus on developing innovative therapeutic approaches for newly diagnosed patients.
- Novel therapeutic combinations
- First-line treatment strategies
- Hematologic malignancies
Their research encompasses comprehensive evaluation of treatment outcomes in hematologic disorders.
Myeloid Disorders
The investigator focuses on myelodysplastic syndromes, particularly addressing advanced disease states such as MDS with excess blasts-2.
- Disease progression management
- Treatment optimization
- Risk assessment strategies
Their work aims to enhance therapeutic outcomes for patients with complex myeloid conditions.
Treatment Innovation
The investigator explores combination approaches incorporating targeted therapies with standard treatment protocols in hematologic malignancies.
- Targeted therapeutic agents
- Induction therapy optimization
- Consolidation strategies
Their research focuses on improving survival outcomes through innovative treatment combinations.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.